Early Notification & Brand Change Entecavir
As advised via Pharmac decision announced 9 March 2018 there is to be a change in the listing and future sole supply.
New listing from 1 August 2018
Entecavir Sandoz Tab 0.5 mg 30 Pharmacode 2549301 Schedule price $52.00
Baraclude Tab 0.5 mg 30 BMS Pharmacode 2222159 Schedule price $400.00
Reference pricing will apply to incumbent from 1 October 2018. Delisting from HML 1 November 2018 and from Pharmaceutical Schedule 1 January 2019.
Hospital Sole Supply status from 1 November 2018.
STAT (all-at-once) rule applies from 1 July 2018
We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted or 1 October 2018, whichever comes first.
Benefit of staying with incumbent
With a variable or reducing margin every cent counts therefore, 4% of $400.00 = $16.00 compared to 3% of $52.00 = $1.5600 (excludes the per pack fee as that is the same for both products) Overall advantage per pack $14.44 in dispensing Baraclude.
You simply need to manage your stock so that you have ZERO stock at time of reference pricing being 1 October 2018.
As of the date of this notification ProPharma / PWR cannot accept Baraclude Tabs 0.5 mg 30 for credit under any circumstances.
Brand Switch Fee applies from 1 January 2019 to 31 March 2019.
Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred.
Together we can make this a seamless and painless transition.
We thank you in anticipation of your ongoing support.